Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition

Clinical Cancer Research

Volumn 16, Issue 18, 2010, Pages 4654-4665

  Gualberto, Antonio ^a,b   Dolled Filhart, Marisa ^c   Gustavson, Mark ^c   Christiansen, Jason ^c   Wang, Yu Fen ^d   Hixon, Mary L ^b   Reynolds, Jennifer ^a   McDonald, Sandra ^a   Ang, Agnes ^c   Rimm, David L ^c   Langer, Corey J ^f   Blakely, Johnetta ^g   Garland, Linda ^h   Paz Ares, Luis G ⁱ   Karp, Daniel D ^e   Lee, Adrian V ^d  

^a PFIZER INC   (United States)

^b BROWN UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g WEST CLINIC   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; FIGITUMUMAB; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PROTEIN KINASE B; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELLULAR DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HORMONE ANTAGONISTS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MOLECULAR DIAGNOSTIC TECHNIQUES; NIH 3T3 CELLS; PROGNOSIS; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS;

EID: 77956665243     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0089     Document Type: Article

References (34)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
2. Favoni RE, De Cupis A, Ravera F, et al. Expression and function of the insulin like growth factor 1 system in human non small cell lung cancer and normal lung cell lines. Int J Cancer 1994;56:858-66. (Pubitemid 24102754)
3. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Serum insulin like growth factor(IGF) and IGF binding protein levels and risk of lung cancer: a case control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev 2002;11:1413-18. (Pubitemid 35340378)
4. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology:early clinical trial results and future directions. Oncogene 2009;28:3009-21.
5. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-73.
6. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-22.
7. Karp DD, Pollak MN, Cohen RB, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009;4:1397-403.
8. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-7.
9. Gustavson MD, Bourke-Martin B, Reilly DM, et al. Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis (AQUA). Arch Pathol Lab Med 2009;133:1413-9.
10. Gustavson MD, Bourke-Martin B, Reilly DM, et al. Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis. Appl Immunohistochem Mol Morphol 2009;17:329-37.
11. Reynolds JM, Lloyd DB, Bentivegna SC, Seymour AB, Borzillo GV, Gualberto A. Insulin-like growth factor 1 receptor mutants are inhibited by figitumumab (CP-751-871) in vitro. AACR Molecular Targets and Cancer Therapeutics, 2009, Boston MA, Abstr B119.
12. Chan BT, Lee AV. Insulin receptor substrates (IRSs) and breast tumorigenesis. J Mammary Gland Biol Neoplasia 2008;13:415-22.
13. Kim HJ, Litzenburger BC, Cui X, et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-κB and snail. Mol Cell Biol 2007;27:3165-75.
14. Dziadziuszko R, Merrick DT, Witta SE, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010;28:2174-80. Epub ahead of publication 2010.
15. Cappuzzo F, Tallini G, Finocchiaro G, et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 2010;21:562-7.
16. Cappuzzo F, Toschi L, Tallini G, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006;17:1120-7.
17. Merrick DT, Dziadziuszko R, Szostakiewicz B, et al. High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2007;25:Abst 7550.
18. Ludovini V, Bellezza G, Pistola L, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 2009;20:842-9.
19. Gualberto A, Dolled-Filhart MP, Hixon ML, et al. Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC. J Clin Oncol 2009;27:15s, (suppl;abstr 8091).
20. Gong Y, Yao E, Shen R, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009;4:e7273.
21. Zha J, O'Brien C, Savage H, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 2009;8:2110-21.
22. Litzenburger BC, Kim HJ, Kuiatse I, et al. BMS-536924 reverses IGFIR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res 2009;15:226-37.
23. Huang F, Greer A, Hurlburt W, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009;69:161-70.
24. Chang Q, Li Y, White MF, Fletcher JA, Xiao S. Constitutive activation of insulin receptor substrate-1 is a frequent event in human tumors: therapeutic implications. Cancer Res 2002;62:6035-38. (Pubitemid 35244449)
25. Mukohara T, Shimada H, Ogasawara N, et al. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett 2009;282:14-24.
26. Julien-Grille S, Moore R, Denat L, et al. The role of insulin-like growth factors in the epithelial to mesenchymal transition. In: Savagner P, editor. Rise and fall of the epithelial phenotype: Concepts of epithelial-mesenchymal transition. Montpellier: Landes Bioscience; 2005. p. 215-35.
27. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of β-catenin. Proc Natl Acad Sci U S A 2000;97:12103-8.
28. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L. IGF-II induces rapid β-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001;20:4942-50. (Pubitemid 32769784)
29. Canonici A, Steelant W, Rigot V, et al. Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin. Int J Cancer 2008;122:572-82.
30. Bremnes RM, Veve R, Gabrielson E, et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002;20:2417-28.
31. Hixon ML, Gualberto A, Demers L, et al. Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871). J Clin Oncol 2009;27:15s, (suppl;abstr 3539).
32. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623.
33. Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 2008;111:79-91. (Pubitemid 352009232)
34. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281-9.